GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (FRA:PCJ) » Definitions » Operating Cash Flow per Share

Abeona Therapeutics (FRA:PCJ) Operating Cash Flow per Share : €-1.28 (TTM As of Sep. 2024)


View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics Operating Cash Flow per Share?

Abeona Therapeutics's operating cash flow per share for the three months ended in Sep. 2024 was €-0.23. Abeona Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Sep. 2024 was €-1.28.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 43.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 38.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Abeona Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

FRA:PCJ' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -48.5   Med: 18.2   Max: 81.9
Current: 43.2

During the past 13 years, Abeona Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 81.90% per year. The lowest was -48.50% per year. And the median was 18.20% per year.

FRA:PCJ's 3-Year OCF Growth Rate is ranked better than
88.11% of 1194 companies
in the Biotechnology industry
Industry Median: 3.6 vs FRA:PCJ: 43.20

Abeona Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Abeona Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics Operating Cash Flow per Share Chart

Abeona Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.07 -7.77 -14.76 -5.22 -1.59

Abeona Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.22 -0.33 -0.49 -0.23 -0.23

Competitive Comparison of Abeona Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Abeona Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abeona Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's Price-to-Operating-Cash-Flow falls into.



Abeona Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Abeona Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )=Cash Flow from Operations (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=-33.937/21.380
=-1.59

Abeona Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Sep. 2024 )=Cash Flow from Operations (Q: Sep. 2024 )/Shares Outstanding (Diluted Average) (Q: Sep. 2024 )
=-11.023/48.082
=-0.23

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abeona Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Abeona Therapeutics Business Description

Traded in Other Exchanges
Address
6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

Abeona Therapeutics Headlines

No Headlines